Support Centre

Testing uses a simple cheek (buccal) swab, with no blood draw and no clinic visit required for sample collection. A collection kit is posted to you with prepaid return packaging. The process takes under five minutes.

Results are typically available within 2–3 weeks from the date your returned sample is received by the laboratory. You will receive an email notification when your report is ready for clinical review. If you have not received notification within 3 weeks of returning your kit, please contact the TBMH-PGx team directly.

At the time of publication, Medicare does not provide a rebate for pharmacogenomics testing in Australia. The testing is privately funded. As of June 3, 2026, Medibank publishes a PGx claim guide for eligible members, while Bupa promotes current pharmacogenomics access through Blua. Insurer terms can change, and the coverage landscape is evolving; the RCPA website remains a useful Australian reference point.

A clinician referral is strongly recommended to ensure your results are interpreted in the context of your full clinical picture. Pharmacogenomic results without clinical context can be difficult to act on appropriately. Our team will request the name of your referring or treating clinician when you order.

Your underlying genetic variants do not change. DNA is stable throughout your life. However, the clinical recommendations associated with your genotype may be updated as new evidence emerges. CPIC and DPWG guidelines are regularly reviewed and updated. Your clinician will always apply the most current guidelines to your stable genetic result.

No, pharmacogenomic results are a clinical tool that informs prescribing decisions, but they do not replace clinical judgement. The same genotype can lead to different recommendations depending on the indication, comorbidities, and other medications. Results must always be reviewed by a qualified clinician in the context of your full medical history.

Yes. Your genetic data is stored securely in compliance with the Australian Privacy Act 1988 and the relevant clinical privacy obligations. It is not shared with third parties, employers, or insurers without your explicit written consent. Please contact the TBMH-PGx team for a copy of the full Privacy and Consent Policy before ordering if you have specific concerns.

Yes. TBMH-PGx accepts referrals from GPs, psychiatrists, neurologists, and other treating clinicians. Patients can use the secure checkout page first, and TBMH will collect the treating-clinician details during follow-up onboarding before report delivery. For bulk referral arrangements or clinical queries, please contact the team directly.

Standard genetic testing (e.g. for hereditary disease risk) looks for variants associated with disease susceptibility. Pharmacogenomics specifically examines variants that affect how your body processes medications, not disease risk. The two types of testing serve different clinical purposes and are not interchangeable.